RE:RE:Upcoming Discussion ... Regardless of easier or harder - both acute and chronic are huge markets on their own. Also, acute is a short window for painkiller usage which makes OTENA a perfect candidate. Chronic is more complex in regimen design w.r.t. the liver (IMO) and success in chronic will come from success in acute ... first.
Remember - as far as I'm concerned ... I'll take a chronic flare-up drug in the end. I'm not selfish ... hahaha!
Also remember - what some call a debacle may have been unavoidable. If you can't see the same effect in animals as in humans then you are at a disadvantage.
The difference may still prove to be the elegance in the pivot. This pivot has a risk-reducing effect that may come with 20 year IP ... in double the market size. That's the bet I made in 2019 and going directly to 20 years patent was my hope. I didn't really get excited about a 5 year patent.
So ... back to our fully-funded P2 ... that's the key that can drive excitement in various directions. I think we need Jan 18th in order to really understand where we're going. We need it (along with P2 results) to excite potential partners.
Let's see.